Insulet Corporation (PODD)

NASDAQ: PODD · USD

$149

-1.20 (-0.8%)· Recorded snapshot

英語版にフォールバックJA

翻訳中のため英語版を表示しています

このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

StockMarketAgent Research · Analyzed 2026-10-14

Our latest published analysis: PODD rated Buy

Insulet Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$165 / share

Potential value

$210 / share

Upside to FV

+23.1%

from $149

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$9.3B
Revenue (ttm)	3.1B
Net income (ttm)	375.3M
EPS (ttm)	$5.30
Shares out	69.4M
P/E (trailing)	28.1x
P/E (forward)	55.0x
Volume	686,221
Beta	1.10

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.1B
Net income (ttm): 375.3M
EPS (ttm): $5.30
P/E (trailing): 28.1x
P/E (forward): 55.0x
Market cap: $9.3B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$1.04B	$1.06B	$1.70B	$2.07B	$2.71B	+27.0%
Gross profit	$752.1M	$805.6M	$1.16B	$1.45B	$1.94B	+26.7%
Operating income	$126.0M	$37.6M	$220.1M	$308.9M	$473.8M	+39.3%
Net income	$16.8M	$4.6M	$206.3M	$418.3M	$247.1M	+95.8%
EPS (diluted)	$0.24	$0.07	$2.94	$5.78	$3.48	+95.1%
EBITDA	$139.6M	$109.0M	$323.6M	$423.7M	$509.6M	+38.2%
R&D	$160.1M	$180.2M	$205.0M	$219.6M	$301.1M	+17.1%
SG&A	$466.0M	$587.8M	$734.8M	$917.2M	$1.17B	+25.7%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ARM	Arm Holdings plc	252B	240.8x	48.2x	14.2%	—	+31.0%	売り
ASML	ASML Holding N.V.	647.9B	42.6x	14.2x	92.1%	+17.2%	+57.7%	売り
DDOG	Datadog, Inc.	100B	567.7x	25.6x	2.9%	+39.0%	+75.6%	売り
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	売り
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	縮小
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	縮小

Base and Bull scenarios

Base55%

Price target

$164.82

+23.1% from spot

The modal expected path reflects consensus-aligned execution: FY2026 revenue of $3,287.08M (21.38% growth) and FY2027 revenue of $3,735.00M (13.63% growth), guided by mid-teens exit growth. Operating margins expand ~100 basis points annually from 17.5% in FY2025 to 22.5% by FY2030, supporting diluted EPS of $6.51 in FY2026 and $7.73 in FY2027, yielding our house Fair value of $164.82.

FY2026 revenue growth of 21.38% reaching $3,287M
FY2027 revenue growth decelerating to 13.63% reaching $3,735M
Annual operating margin expansion of ~100 bps from 17.5% to 22.5%
Cost of equity of 9.45% and terminal P/E of 25.0x

Bull20%

Price target

$210.43

+57.1% from spot

Accelerated adoption of Omnipod 5 across intensive and basal Type 2 diabetes segments combines with rapid international expansion, driving consolidated top-line growth above 25% annually. Automated manufacturing lines achieve optimal yield efficiencies, expanding operating margins beyond 24% and compounding diluted EPS above 25% annually toward our high-case valuation of $210.43,.

Full-year revenue growth exceeding 22%
International Omnipod revenue growth compounding above 32%
Operating margins expanding through manufacturing efficiencies and operating leverage
Diluted EPS CAGR exceeding 25% annually

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($164.82). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
8.5%	$171	$177	$184	$193	$203
9.0%	$163	$168	$174	$181	$189
9.5%	$156	$160	$165	$171	$177
10.0%	$149	$153	$157	$162	$168
10.5%	$143	$147	$150	$154	$159

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E55

P25 n/aP50 n/aP75 n/a

Trailing P/E26.2

P25 n/aP50 n/aP75 n/a

ROE26

P25 n/aP50 n/aP75 n/a

ROIC20.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PODD indicators

Market & fundamental data

Available fields

271

Groups with data

Currency

USD

Showing 271 of 271 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001145197
Company name	Insulet Corporation
Country	United States
Country code	US
CUSIP number	45784P101
Earnings date	2026-11-04
Earnings time	bmo
Employees	5,400
Employees change	1,500
Employees growth	38.46%
Enterprise value	$10.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2000
In index	SP500
Industry	Medical Devices
IPO date	2007-05-15
Is primary listing	Yes
Is SPAC	No
ISIN number	US45784P1012
Last 10-K release date	2026-02-18
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$10.3B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$148.63
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	PODD
U.S. state	Massachusetts
Website	https://www.insulet.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	25.32x
Average P/E ratio (10Y)	1,958.41x
Average P/E ratio (3Y)	60.11x
Average P/E ratio (5Y)	2,386.54x
Earnings yield	3.56%
EV/Earnings	28.75x
EV/EBIT	20.93x
EV/EBITDA	17.55x
EV/FCF	36.74x
EV/Sales	3.53x
FCF / EV yield	2.72%
FCF yield	2.85%
Forward EV/Sales	3.09x
Forward P/E	21.7x
Forward P/S	2.95x
Graham number	49.43711
Graham upside	-66.75%
Industry forward P/E	19.81x
Industry P/E	39.28x
Lynch fair value	$132.42
Lynch upside	-10.93%
P/(FCF - SBC) ratio	47.78x
P/(OCF - SBC) ratio	23.8x
P/B ratio	7.31x
P/E ratio	28.06x
P/FCF ratio	35.11x
P/OCF ratio	20.17x
P/S ratio	3.38x
PEG ratio	1.09x
Price / tangible book value	8.21x
Price/EBITDA ratio	16.77x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	16.89%
EBITDA margin	20.14%
Effective tax rate	24.14%
FCF margin	9.62%
Gross margin	71.07%
Operating margin	16.89%
Pretax margin	16.2%
Profit margin	12.29%
Profit per employee	$69,500
Profitable quarters	15
Profitable years	8
Revenue per employee	$565,444
ROA	9.71%
ROA (5Y)	5.52%
ROCE	21.3%
ROE	26.02%
ROE (5Y)	19.81%
ROIC	20.92%
ROIC (5Y)	13.77%
SBC / revenue	2.55%
Tax / revenue	3.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	59.41%
EPS growth (Q)	328.59%
EPS growth (QoQ)	5.38%
EPS growth 3Y	80.81%
EPS growth quarters	4
EPS growth years	0
FCF growth	-27.46%
FCF growth (Q)	-68.58%
FCF growth (QoQ)	-37.54%
FCF growth 3Y	113.45%
Gross profit growth	31.07%
Gross profit growth (Q)	24.41%
Gross profit growth 3Y	30.84%
Gross profit growth 5Y	26.76%
Net income growth	58.96%
Net income growth (Q)	322.22%
Net income growth (QoQ)	4.28%
Net income growth 3Y	81.37%
Net income growth quarters	4
Net income growth years	0
OCF growth	-0.95%
OCF growth (Q)	-55.01%
OCF growth (QoQ)	-22.32%
OCF growth 3Y	49.86%
OCF growth 5Y	63.02%
Operating income growth	30.9%
Operating income growth (Q)	7.1%
Operating income growth 3Y	64.51%
Operating income growth 5Y	54.22%
Revenue growth	29.41%
Revenue growth (Q)	23.51%
Revenue growth (QoQ)	5.25%
Revenue growth 10Y	25.16%
Revenue growth 3Y	27.73%
Revenue growth 5Y	25.12%
Revenue growth quarters	43
Revenue growth years	11

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-217.5M
Depreciation and amortization	$99.3M
EBIT	$515.6M
EBITDA	$614.9M
EPS	$5.30
FCF per share	$4.23
Financing cash flow	$-845.4M
Free cash flow	$293.7M
Free cash flow minus SBC	$215.8M
Gross profit	$2.2B
Income taxes	$119.4M
Investing cash flow	$-248.9M
Net borrowing	$-609M
Net cash flow	$-586.7M
Net income	$375.3M
Operating cash flow minus SBC	$433.3M
Operating income	$515.6M
Revenue	$3.1B
Stock-based compensation	$77.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	8.46
Book value per share	$20.51
Debt / EBITDA	1.62
Debt / equity	0.71
Debt / FCF	3.46
Goodwill	$51.6M
Interest coverage	8.77
Long-term assets	$1.3B
Long-term liabilities	$998.7M
Net cash (debt)	$-480.6M
Net cash / market cap	-4.66%
Net debt / EBITDA	0.78
Net debt / equity	0.34
Net debt / FCF	1.64
Piotroski F-Score	8
Property, plant and equipment	$858.6M
Shareholders' equity	$1.4B
Tangible book value	$1.3B
Tangible book value per share	$18.10
Total assets	$3.2B
Total cash	$534.9M
Total debt	$1B
Total liabilities	$1.7B
WACC	9.78%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.92
Current assets	$1.8B
Current liabilities	$744.2M
Current ratio	2.48
Inventory turnover	1.9
Net working capital	$588.9M
Quick ratio	1.51
Working capital	$1.1B
Working capital turnover	2.57

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.19%
Dividend yield	0%
Shareholder yield	1.19%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	302.08%
10Y return CAGR	14.93%
10Y total return	302.08%
150-day SMA	$157.02
15Y price change	819.49%
15Y return CAGR	15.94%
15Y total return	819.49%
1D price change	-0.8%
1M price change	9.49%
1M total return	9.49%
1W price change	4.49%
1W total return	4.49%
1Y price change	-54.25%
1Y return CAGR	-54.28%
1Y total return	-54.25%
20-day SMA	$140.02
200-day SMA	$180.09
3M price change	-9.67%
3M total return	-9.67%
3Y price change	11.71%
3Y return CAGR	3.76%
3Y total return	11.71%
50-day SMA	$140.84
50-day SMA vs 200-day SMA	50under200
52-week high	$354.88
52-week high date	2025-11-20
52-week low	$126.40
52-week low date	2026-08-05
5Y price change	-50.21%
5Y return CAGR	-13.02%
5Y total return	-50.21%
6M price change	-20.85%
6M total return	-20.85%
All-time high	$354.88
All-time high date	2025-11-20
All-time low	$2.57
All-time low date	2009-03-09
Average true range (ATR)	$4.45
Average volume	1.5M
Beta (1Y)	-0.68
Beta (2Y)	0.31
Beta (5Y)	1.1
Change from 52-week high	-58.12%
Change from 52-week low	17.59%
Change from all-time high	-58%
Change from all-time low	5,699.61%
Change from open	-0.11%
Day's gap	-0.69%
Dollar volume	$102M
High price	$150.42
Low price	$147.36
Monthly RSI	37.97
Open price	$148.80
Position in 52-week range	41.5%
Premarket change	-0.05%
Premarket close	$149.83
Premarket price	$149.75
Premarket volume	555
Previous close	$149.83
Price vs 150-day SMA	-5.08%
Price vs 20-day SMA	6.45%
Price vs 200-day SMA	-17.24%
Price vs 50-day SMA	5.83%
Relative volume	0.46
RSI	64.94
Sharpe ratio	-1.6
Sharpe ratio (3Y)	0.12
Sharpe ratio (5Y)	-0.19
Sortino ratio	-1.82
Sortino ratio (3Y)	0.31
Sortino ratio (5Y)	-0.14
Volume	686.2K
Weekly RSI	41.94
YTD price change	-47.56%
YTD total return	-47.56%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	69.1M
Float percentage	99.58%
Shares change (QoQ)	-1.14%
Shares change (YoY)	-1.19%
Shares held by insiders	0.32%
Shares held by institutions	105.7%
Shares outstanding	69.4M
Short % of float	8.15%
Short % of shares	8.12%
Short ratio	3.1 days

Deeper analysis on PODD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this PODD report

What is the latest published PODD stock rating?

Insulet Corporation is shown with Buy in the latest published report, analyzed 2026-10-14. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PODD analysis?

The full latest published report, analyzed 2026-10-14, lives at /stocks/PODD/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for PODD?

The latest published report analyzed 2026-10-14 gives PODD a fair value of USD 165 and a potential value of USD 210. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the PODD page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-14). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuyPODD · Fair value $165+23.1%

Read full analysis →

Insulet Corporation (PODD)

Our latest published analysis: PODD rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · PODD

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All PODD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PODD

Frequently asked questions

レーティング履歴

Category	Score	Reading
Valuation	7.5
Management	6.5
Balance Sheet	7.5
Profitability	7.5
Revenue Growth	7.5
Risk Assessment	7.0
Competitive Moat	7.5
Earnings Quality	9.0
Capital Efficiency	7.5